New drug aims to tame dangerous heart rhythms in genetic disorder

NCT ID NCT07277582

First seen Jan 06, 2026 · Last updated May 16, 2026 · Updated 26 times

Summary

This study tests an experimental drug, THRV-1268, in 64 people with Long QT Syndrome Type 2 (LQTS 2), a genetic heart condition that can cause dangerous rhythms and sudden cardiac arrest. Participants take the drug twice daily for up to 6 weeks to see if it safely shortens the QT interval, a measure of heart electrical recovery. The goal is to find the best dose that reduces risk without serious side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LONG QT SYNDROME (LQTS) 2 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Heart Center Clinical Research Program | MGH

    RECRUITING

    Boston, Massachusetts, 02114, United States

  • Honor Health Research and Innovation Institute

    RECRUITING

    Scottsdale, Arizona, 85258, United States

  • Mayo Clinic

    RECRUITING

    Rochester, Minnesota, 55905, United States

  • University of California San Francisco

    RECRUITING

    San Francisco, California, 94143, United States

  • University of Illinois Chicago

    RECRUITING

    Chicago, Illinois, 60612, United States

  • Wilmington Health

    RECRUITING

    Wilmington, North Carolina, 28401, United States

Conditions

Explore the condition pages connected to this study.